Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Glioblastoma 80Prostatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 54Breast Neoplasms 54Esophageal Neoplasms 48Rectal Neoplasms 42Lung Neoplasms 42Brain Neoplasms 34Squamous Cell Carcinoma of Head and Neck 33Head and Neck Neoplasms 33Gliosarcoma 31Pancreatic Neoplasms 29Uterine Cervical Neoplasms 28Neoplasms 25Glioma 24Neoplasm Metastasis 23Sarcoma 22Oropharyngeal Neoplasms 21Esophageal Squamous Cell Carcinoma 20Melanoma 19Astrocytoma 18Adenocarcinoma Of Esophagus 15Stomach Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Squamous Cell 12Urinary Bladder Neoplasms 11Mouth Neoplasms 11Lymphoma, Follicular 11Central Nervous System Neoplasms 11Carcinoma 11

Interventions

Cytarabine 6Vincristine 4Methotrexate 4Mercaptopurine 4pegaspargase 3merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3azathiopurine 3auricularum 3Thioguanine 3Dexamethasone 3Daunorubicin 3Cyclophosphamide 3Calcium Dobesilate 3Asparaginase 3prednylidene 2blinatumomab 2asparaginase erwinia chrysanthemi recombinant 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Leucovorin 2Hydrocortisone 2Etoposide 2Doxorubicin 2hydrocortisone hemisuccinate 1deltacortene 1calaspargase pegol 1Spinal Puncture 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Down Syndrome × Radiation × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡